Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 360 entries
View as:

Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users

Phase: N/A Priority: Normal
NCT ID: NCT00828659 Org: User:
Start: 12/31/08 End: 04/30/09 Due: 04/30/10

Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT01378416 Org: User:
Start: 04/30/05 End: 06/30/07 Due: 06/30/08

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Phase: N/A Priority: Normal
NCT ID: NCT01332266 Org: User:
Start: 09/19/11 End: 09/04/17 Due: 09/04/18

A Study to Demonstrate Bioequivalence Between a 12-mg Dose of an Oral Suspension Formulation of Perampanel and a 12-mg Tablet Formulation of Perampanel Under Fasted and Fed Conditions in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02279485 Org: User:
Start: 09/30/14 End: 01/31/15 Due: 01/31/16

BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management

Phase: N/A Priority: Normal
NCT ID: NCT00603902 Org: User:
Start: 01/31/08 End: 08/31/09 Due: 08/31/10

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01127451 Org: User:
Start: 06/22/10 End: 04/07/15 Due: 04/07/16

Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT00941109 Org: User:
Start: 12/31/09 End: 09/30/12 Due: 09/30/13

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02207790 Org: User:
Start: 07/31/14 End: 10/31/14 Due: 10/31/15

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT02171260 Org: User:
Start: 07/31/14 End: 01/28/16 Due: 01/28/17

Evaluation of Eperisone HCl in the Treatment of Acute Musculoskeletal Spasm Associated With Low Back Pain - A Double Blind, Randomised, Placebo Controlled Clinical Trial

Phase: N/A Priority: Normal
NCT ID: NCT00327730 Org: User:
Start: 04/30/06 End: 06/30/06 Due: 06/30/07

A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

Phase: N/A Priority: Normal
NCT ID: NCT01463098 Org: User:
Start: 10/05/11 End: 08/11/12 Due: 08/11/13

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02811861 Org: User:
Start: 10/13/16 End: 03/31/26 Due: 03/31/27

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Phase: N/A Priority: Normal
NCT ID: NCT00448539 Org: User:
Start: 03/15/07 End: 05/14/10 Due: 05/14/11

A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)

Phase: N/A Priority: Normal
NCT ID: NCT01830868 Org: User:
Start: 03/31/12 End: 08/31/13 Due: 08/31/14

A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00282399 Org: User:
Start: 10/31/06 End: 02/28/09 Due: 02/28/10

Study of Irofulven in Patients With Hormone-refractory Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00124566 Org: User:
Start: 06/30/04 End: 12/31/09 Due: 12/31/10

A Study of Oral E1018 in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT06854042 Org: User:
Start: 02/26/25 End: 12/23/25 Due: 12/23/26

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01177540 Org: User:
Start: 03/03/11 End: 07/19/13 Due: 07/19/14

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01439282 Org: User:
Start: 08/31/11 End: 05/31/14 Due: 05/31/15

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Phase: N/A Priority: Normal
NCT ID: NCT03288129 Org: User:
Start: 08/23/17 End: 04/27/21 Due: 04/27/22

A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.

Phase: N/A Priority: Normal
NCT ID: NCT02578316 Org: User:
Start: 06/30/09 End: 10/31/10 Due: 10/31/11

A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

Phase: N/A Priority: Normal
NCT ID: NCT02915783 Org: User:
Start: 02/20/17 End: 11/02/21 Due: 11/02/22

An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02116907 Org: User:
Start: 05/31/14 End: 09/30/14 Due: 09/30/15

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01328249 Org: User:
Start: 03/03/11 End: 10/19/17 Due: 10/19/18

A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis

Phase: N/A Priority: Normal
NCT ID: NCT00046072 Org: User:
Start: 10/31/01 End: 04/30/05 Due: 04/30/06